Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line Treatment for Patients with BRAF V600E-mutated mCRC By Ogkologos - June 25, 2025 437 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR New on NCI’s Websites for April 2024 April 12, 2024 Born Blind With 50% Chance Of Survival, 20-Year-Old Musician Defied All... November 1, 2021 Dwayne Johnson Sends Special “Moana” Message To 3-Yr-Old Battling Cancer. November 21, 2019 Coronavirus reports – Part 8: “Going into hospital during this time... December 18, 2020 Load more HOT NEWS Foodie Fridays: It’s Cucumber Season! Hugh Jackman Stops His Show To Bring Woman With Breast Cancer... Tips from Your Cancer Care Team – Coping with Treatment During... Kinder and more effective – why childhood cancers need specific treatments
